Kyowa Kirin Co Ltd
TSE:4151

Watchlist Manager
Kyowa Kirin Co Ltd Logo
Kyowa Kirin Co Ltd
TSE:4151
Watchlist
Price: 2 523 JPY -0.86% Market Closed
Market Cap: 1.3T JPY
Have any thoughts about
Kyowa Kirin Co Ltd?
Write Note

Kyowa Kirin Co Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Kyowa Kirin Co Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Kyowa Kirin Co Ltd
TSE:4151
Revenue
ÂĄ499B
CAGR 3-Years
14%
CAGR 5-Years
11%
CAGR 10-Years
4%
Takeda Pharmaceutical Co Ltd
TSE:4502
Revenue
ÂĄ4.5T
CAGR 3-Years
10%
CAGR 5-Years
10%
CAGR 10-Years
10%
Daiichi Sankyo Co Ltd
TSE:4568
Revenue
ÂĄ1.8T
CAGR 3-Years
20%
CAGR 5-Years
13%
CAGR 10-Years
8%
Otsuka Holdings Co Ltd
TSE:4578
Revenue
ÂĄ2.3T
CAGR 3-Years
16%
CAGR 5-Years
11%
CAGR 10-Years
4%
Chugai Pharmaceutical Co Ltd
TSE:4519
Revenue
ÂĄ1.1T
CAGR 3-Years
9%
CAGR 5-Years
12%
CAGR 10-Years
10%
Astellas Pharma Inc
TSE:4503
Revenue
ÂĄ2.1T
CAGR 3-Years
18%
CAGR 5-Years
10%
CAGR 10-Years
6%
No Stocks Found

Kyowa Kirin Co Ltd
Glance View

Market Cap
1.3T JPY
Industry
Pharmaceuticals

Kyowa Kirin Co., Ltd. is a global biopharmaceutical company rooted in Japan, well-regarded for its commitment to developing innovative therapies that address unmet medical needs. Founded in 1949, the company has evolved significantly over the decades, transitioning from a traditional pharmaceutical manufacturer to a cutting-edge biotechnology leader. Kyowa Kirin harnesses its expertise in research and development to focus on critical areas such as oncology, immunology, and nephrology, leveraging proprietary technologies to create unique biologics that enhance patient outcomes. With a diverse pipeline of products and a strong emphasis on collaboration, both within Japan and with international partners, the company positions itself as a key player in the rapidly evolving biopharmaceutical landscape. For investors, Kyowa Kirin represents not just a robust financial opportunity but also the embodiment of long-term value creation, reflecting the investment principles of renowned thinkers like Warren Buffett and Charlie Munger. The company maintains a sound financial profile, characterized by steady revenue growth, a solid balance sheet, and a commitment to shareholder returns through dividends and strategic reinvestments. As the global demand for innovative healthcare solutions escalates, Kyowa Kirin's ongoing commitment to R&D, coupled with its strategic alliances and acquisitions, positions it well for sustainable growth and resilience in the face of market fluctuations. Investors seeking to capitalize on the burgeoning biopharmaceutical sector should consider Kyowa Kirin as a potential long-term investment opportunity in a company poised to make a meaningful impact on global health.

Intrinsic Value
3 756.45 JPY
Undervaluation 33%
Intrinsic Value
Price

See Also

What is Kyowa Kirin Co Ltd's Revenue?
Revenue
499B JPY

Based on the financial report for Sep 30, 2024, Kyowa Kirin Co Ltd's Revenue amounts to 499B JPY.

What is Kyowa Kirin Co Ltd's Revenue growth rate?
Revenue CAGR 10Y
4%

Over the last year, the Revenue growth was 19%. The average annual Revenue growth rates for Kyowa Kirin Co Ltd have been 14% over the past three years , 11% over the past five years , and 4% over the past ten years .

Back to Top